MOUNTAIN VIEW, Calif.,
July 27, 2021 /PRNewswire/ --
AliveCor, Inc. ("AliveCor"), a leading innovator in FDA-cleared
personal electrocardiogram (ECG) technology and services,
and Acutus Medical ("Acutus") (Nasdaq: AFIB), an arrhythmia
management company focused on improving the way cardiac arrhythmias
are diagnosed and treated, today announced they will collaborate to
assess the integration of data collection tools across the
cardiology continuum of care that could potentially advance the
field of arrhythmia treatment and disease management.
The management and treatment of complex cardiac arrhythmia
patients continues to be a challenge for physicians and global
healthcare systems and providers. To address these challenges,
Acutus and AliveCor plan to launch in the third quarter of this
year a post-market pilot study in the U.S. to gain insights on how
physicians can utilize the KardiaMobile device to facilitate
pre-ablation and/or post-ablation remote monitoring, which may help
guide decision making in the management of cardiac arrhythmia
patients. This information will enable more informed decisions in
the treatment of complex arrhythmia(s) to potentially improve
patient outcomes.
"Utilizing data from across the continuum of care to complement
our core mapping and therapy technologies furthers our vision to
become the provider-of-choice and democratize the treatment of
complex arrhythmia patients," said Vince
Burgess, President and CEO of Acutus. "AliveCor will be an
excellent partner to help our physicians assess important clinical
patient information as they manage and treat their cardiac
arrhythmia patients."
Acutus offers a broad and innovative portfolio of highly
differentiated electrophysiology tools and products that provide a
complete solution for catheter-based treatment of cardiac
arrhythmias. The company's core technology is the AcQMap 3D Imaging
and Mapping System, the only noncontact mapping system in the world
to enable the creation of full chamber global activation maps in
real-time.
"AliveCor is proud to partner with Acutus to advance
understanding of the use of our shared technologies and how we can
potentially improve the care and monitoring of cardiac patients,"
said Priya Abani, CEO,
AliveCor.
AliveCor's FDA-cleared KardiaMobile device, the most clinically
validated personal ECG solution in the world, has been used by more
than one million people. The KardiaMobile 6L device is the first
and only six-lead personal ECG that detects more arrhythmias than
any other personal ECG device. KardiaMobile 6L provides instant
detection of Atrial Fibrillation, Bradycardia, Tachycardia, Sinus
Rhythm with Supraventricular Ectopy, Sinus Rhythm with Premature
Ventricular Contractions, Sinus Rhythm with Wide QRS and Normal
Heart Rhythm in an ECG. The FDA recently cleared the KardiaMobile
6L device for healthcare professionals to use the device to
calculate patients' QTc interval. The acquisition this year of
CardioLabs, a leading monitoring and cardiac diagnostic service
provider, furthers the mission of AliveCor to extend its
comprehensive cardiological services to patients who are
recommended monitoring devices by their healthcare providers.
About Acutus Medical
Acutus Medical is an
arrhythmia management company focused on improving the way cardiac
arrhythmias are diagnosed and treated. Acutus is
committed to advancing the field of electrophysiology with a
unique array of products and technologies which will enable more
physicians to treat more patients more efficiently and effectively.
Through internal product development, acquisitions and global
partnerships, Acutus has established a global sales presence
delivering a broad portfolio of highly differentiated
electrophysiology products that provide its customers with a
complete solution for catheter-based treatment of cardiac
arrhythmias in each of its geographic markets. Founded in
2011, Acutus is based in Carlsbad,
California.
Follow Acutus Medical on:
- Twitter: @AcutusMedical
- LinkedIn: www.linkedin.com/company/acutus-medical-inc-/
- Facebook: @AcutusMedical
About AliveCor
AliveCor, Inc. is transforming
cardiological care using deep learning. The FDA-cleared
KardiaMobile device is the most clinically validated personal ECG
solution in the world. KardiaMobile 6L provides instant detection
of Atrial Fibrillation, Bradycardia, Tachycardia, Sinus Rhythm with
Supraventricular Ectopy, Sinus Rhythm with Premature Ventricular
Contractions, Sinus Rhythm with Wide QRS and Normal Heart Rhythm in
an ECG. Kardia is the first AI-enabled platform to aid patients and
clinicians in the early detection of atrial fibrillation, the most
common arrhythmia and one associated with a highly elevated risk of
stroke. AliveCor's enterprise platform allows third party providers
to manage their patients' and customers' heart conditions simply
and profitably using state-of-the-art tools that provide easy
front-end and back-end integration to AliveCor technologies.
AliveCor protects its customers with stringent data security
and compliance practices, achieving HIPAA compliance and SOC2 Type
1 and Type 2 attestations. AliveCor is a privately held company
headquartered in Mountain View,
Calif. "Consumer" or "personal" ECGs are ECG devices
available for direct sale to consumers. For more information, visit
alivecor.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/alivecor-and-acutus-medical-partner-to-evaluate-management-and-treatment-of-cardiac-arrhythmias-301341945.html
SOURCE AliveCor, Inc.; Acutus Medical